RDY vs. HLN

Last updated Apr 2, 2026

Compare and contrast key facts about Dr. Reddy's Laboratories Limited (RDY) and Haleon plc (HLN).

Performance

RDY vs. HLN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dr. Reddy's Laboratories Limited (RDY) and Haleon plc (HLN). The values are adjusted to include any dividend payments, if applicable.

RDY vs. HLN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
RDY Dr. Reddy's Laboratories Limited	-4.06%	-10.53%	14.13%	36.47%	-5.69%
HLN Haleon plc	-1.38%	7.84%	17.99%	4.21%	7.96%

Fundamentals

Market Cap RDY : $11.22B HLN : $44.68B
EPS RDY : $67.92 HLN : $0.62
PE Ratio RDY : 0.20 HLN : 16.16
PEG Ratio RDY : 0.01 HLN : 2.50
PS Ratio RDY : 0.03 HLN : 2.33
PB Ratio RDY : 0.03 HLN : 2.72
Total Revenue (TTM) RDY : $345.83B HLN : $19.27B
Gross Profit (TTM) RDY : $188.26B HLN : $12.29B
EBITDA (TTM) RDY : $93.77B HLN : $4.76B

Returns By Period

In the year-to-date period, RDY achieves a -4.06% return, which is significantly lower than HLN's -1.38% return.

RDY

• 1D: -2.74%
• 1M: -6.33%
• YTD: -4.06%
• 6M: -5.14%
• 1Y: 3.00%
• 3Y*: 6.72%
• 5Y*: 2.48%
• 10Y*: 4.79%

HLN

• 1D: -0.40%
• 1M: -8.28%
• YTD: -1.38%
• 6M: 10.65%
• 1Y: -0.34%
• 3Y*: 8.45%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RDY vs. HLN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RDY

RDY Risk / Return Rank: 41
RDY Sharpe Ratio Rank: 44
RDY Sortino Ratio Rank: 36
RDY Omega Ratio Rank: 37
RDY Calmar Ratio Rank: 44
RDY Martin Ratio Rank: 43

HLN

HLN Risk / Return Rank: 36
HLN Sharpe Ratio Rank: 39
HLN Sortino Ratio Rank: 32
HLN Omega Ratio Rank: 32
HLN Calmar Ratio Rank: 39
HLN Martin Ratio Rank: 39

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RDY vs. HLN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Dr. Reddy's Laboratories Limited (RDY) and Haleon plc (HLN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RDY	HLN	Difference
Sharpe ratio Return per unit of total volatility	0.13	-0.01	+0.14
Sortino ratio Return per unit of downside risk	0.33	0.14	+0.19
Omega ratio Gain probability vs. loss probability	1.04	1.02	+0.03
Calmar ratio Return relative to maximum drawdown	0.14	-0.06	+0.20
Martin ratio Return relative to average drawdown	0.25	-0.11	+0.36
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RDY vs. HLN - Sharpe Ratio Comparison

The current RDY Sharpe Ratio is 0.13, which is higher than the HLN Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of RDY and HLN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RDY	HLN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.13	-0.01	+0.14
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.11	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.18	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.36	0.41	-0.05

Correlation

The correlation between RDY and HLN is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RDY vs. HLN - Dividend Comparison

RDY's dividend yield for the trailing twelve months is around 0.68%, less than HLN's 1.76% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
RDY Dr. Reddy's Laboratories Limited	0.68%	0.65%	0.60%	1.39%	1.48%	1.04%	0.46%	0.71%	0.00%	0.78%	0.62%	0.63%
HLN Haleon plc	1.76%	1.73%	1.65%	1.26%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

RDY vs. HLN - Drawdown Comparison

The maximum RDY drawdown since its inception was -60.62%, which is greater than HLN's maximum drawdown of -24.83%. Use the drawdown chart below to compare losses from any high point for RDY and HLN.

Drawdown Indicators

	RDY	HLN	Difference
Max Drawdown Largest peak-to-trough decline	-60.62%	-24.83%	-35.79%
Max Drawdown (1Y) Largest decline over 1 year	-19.60%	-23.11%	+3.51%
Max Drawdown (5Y) Largest decline over 5 years	-35.25%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-47.13%	—	—
Current Drawdown Current decline from peak	-19.52%	-12.09%	-7.43%
Average Drawdown Average peak-to-trough decline	-21.94%	-7.99%	-13.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.96%	12.54%	-1.58%

Volatility

RDY vs. HLN - Volatility Comparison

Dr. Reddy's Laboratories Limited (RDY) has a higher volatility of 7.69% compared to Haleon plc (HLN) at 7.14%. This indicates that RDY's price experiences larger fluctuations and is considered to be riskier than HLN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RDY	HLN	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.69%	7.14%	+0.55%
Volatility (6M) Calculated over the trailing 6-month period	16.19%	16.43%	-0.24%
Volatility (1Y) Calculated over the trailing 1-year period	23.81%	23.67%	+0.14%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	22.93%	24.04%	-1.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	26.44%	24.04%	+2.40%

Financials

RDY vs. HLN - Profitability Comparison

The chart below illustrates the profitability comparison between Dr. Reddy's Laboratories Limited and Haleon plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RDY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Dr. Reddy's Laboratories Limited reported a gross profit of 44.23B and revenue of 87.27B. Therefore, the gross margin over that period was 50.7%.

HLN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Haleon plc reported a gross profit of 3.59B and revenue of 5.52B. Therefore, the gross margin over that period was 65.0%.

RDY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Dr. Reddy's Laboratories Limited reported an operating income of 14.24B and revenue of 87.27B, resulting in an operating margin of 16.3%.

HLN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Haleon plc reported an operating income of 1.25B and revenue of 5.52B, resulting in an operating margin of 22.7%.

RDY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Dr. Reddy's Laboratories Limited reported a net income of 12.10B and revenue of 87.27B, resulting in a net margin of 13.9%.

HLN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Haleon plc reported a net income of 855.69M and revenue of 5.52B, resulting in a net margin of 15.5%.